SCHEMBL753341

SCHEMBL753341

COC(=O)c1ccc(Oc2ccc([C@@H](C)[C@@](O)(c3ccc(=O)n(C)c3)C(F)(F)F)c(Cl)c2Cl)cc1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.36
ALDH1A1 P00352 4/20 0.34
HPGD P15428 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
KDM4E B2RXH2 3/20 0.33
MAPT P10636 2/20 0.33
SCN8A Q9UQD0 1/20 0.33
SCN10A Q9Y5Y9 1/20 0.33
BRD4 O60885 1/20 0.32
NR1H2 P55055 1/20 0.32
NR1H3 Q13133 1/20 0.32
NPBWR1 P48145 1/20 0.32
MAPK1 P28482 1/20 0.32
KMT2A Q03164 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
TSHR P16473 1/20 0.31
MET P08581 1/20 0.30
ALK Q9UM73 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL480403 1.00 LMNA (0.36) LMNAALDH1A1HPGDNPSR1KDM4E
SCHEMBL754530 0.91 PTGER4 (0.34) ALDH1A1SCN8ASCN10ABRD4TSHR
SCHEMBL734303 0.91 PTGER4 (0.34) ALDH1A1SCN8ASCN10ABRD4TSHR
SCHEMBL480486 0.88 SCN8A (0.36) KDM4ESCN8ASCN10ABRD4MET
SCHEMBL754964 0.88 SCN8A (0.36) KDM4ESCN8ASCN10ABRD4MET
SCHEMBL480948 0.87 LMNA (0.37) LMNAALDH1A1MAPTNR1H2NR1H3
SCHEMBL753268 0.87 LMNA (0.37) LMNAALDH1A1MAPTNR1H2NR1H3
SCHEMBL480727 0.84 MET (0.31) LMNAALDH1A1BRD4KMT2ASMN1; SMN2
SCHEMBL755659 0.83 SCN8A (0.35) SCN8ASCN10AKMT2AMETALK
SCHEMBL733103 0.83 SCN8A (0.35) SCN8ASCN10AKMT2AMETALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
WO-2010108902-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, CRHR1 LMNA 1995/4885ALDH1A1 317/4885HPGD 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.